Physician profile

Gary L Murray

Cardiovascular Disease · Germantown, TN

NPI 1811965429

$1,562.84

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amarin Pharma, INC. $236.47 2019-2021
Novartis Pharmaceuticals Corporation $232.81 2019-2021
Lundbeck LLC $116.23 2019-2020
Pfizer INC. $97.81 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $94.47 2019-2020
Astrazeneca Pharmaceuticals LP $88.32 2019-2020
Sanofi-Aventis U.S. LLC $85.11 2019-2020
Gilead Sciences, INC. $80.17 2019
Abbott Laboratories $75.44 2021
Regeneron Healthcare Solutions, INC. $69.17 2019-2021
Esperion Therapeutics, INC. $66.58 2020-2021
E.R. Squibb & Sons, L.L.C. $62.79 2019-2020
Akcea Therapeutics, INC. $58.88 2019
Astellas Pharma US INC $47.57 2019-2020
Amgen INC. $33.88 2019-2020
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Actelion Pharmaceuticals US, INC. $25.93 2019-2020
Vifor Pharma, INC. $17.57 2019
Boehringer Ingelheim Pharmaceuticals, INC. $16.89 2019
Boston Scientific Corporation $15.79 2019
Janssen Pharmaceuticals, INC $15.59 2019
Ge Healthcare $14.32 2020
Kowa Pharmaceuticals America, INC. $11.05 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary L Murray

$1,562.84

in general payments reported 2019-2025

Years
2019-2021
Top company
Amarin Pharma, INC.

https://glasscript.com/doctor/173339/gary-l-murray

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.